Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20589376 | 0.80 | L3MBTL1 (0.65) | MGAMMRGPRX4L3MBTL1HPGDS | |
| SCHEMBL16914992 | 0.77 | KDM4E (0.54) | MGAML3MBTL1PSMD14P4HA1P4HTM | |
| SCHEMBL13905433 | 0.76 | MGAM (0.49) | MGAMPSMD14HPGDSP4HA1P4HTM | |
| SCHEMBL21945729 | 0.75 | HPGDS (0.60) | MGAML3MBTL1PSMD14HPGDS | |
| SCHEMBL186213 | 0.74 | L3MBTL1 (0.57) | MRGPRX4L3MBTL1P4HA1P4HTM | |
| SCHEMBL29418677 | 0.74 | L3MBTL1 (0.57) | MRGPRX4L3MBTL1P4HA1P4HTM | |
| SCHEMBL538271 | 0.74 | SMN1; SMN2 (0.51) | MGAMMRGPRX4SYKPTPN1 | |
| SCHEMBL29518583 | 0.74 | SMN1; SMN2 (0.51) | MGAMMRGPRX4SYKPTPN1 | |
| SCHEMBL20589994 | 0.74 | HPGDS (0.59) | MGAML3MBTL1PSMD14HPGDS | |
| SCHEMBL13853279 | 0.73 | ALDH1A1 (0.36) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824828-A2 | PYRIDINE BASED COMPOUNDS USEFUL AS INTERMEDIATES FOR PHARMACEUTICAL OR AGRICULTURAL END-PRODUCTS | Peakdale Molecular Limited (GB) | 2007-08-29 | — | — | EP | claimed |
| WO-2006059103-A2 | PYRIDINE BASED COMPOUNDS USEFUL AS INTERMEDIATES FOR PHARMACEUTICAL OR AGRICULTURAL END-PRODUCTS | PEAKDALE MOLECULAR LIMITED (GB) | 2006-06-08 | — | — | WO | claimed |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| CN-1096784-A | Therapeutic agents containing substituted 4(5) -amino-1, 8-diaminonaphthalenes | BOOTS CO PLC (GB) | 1994-12-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PNPO, CYP4B1, PDXK | MGAM 1693/4885MRGPRX4 2715/4885L3MBTL1 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.